| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| ln Vitro |
N-Methylnuciferine (20 μM) was used to pretreat BV2 microglia for 0.5 h, followed by stimulation with 0.5 μg/mL LPS for 24 h. The compound attenuated LPS‑induced NO production and the mRNA levels of pro‑inflammatory cytokines (IL‑1β, IL‑6, TNF‑α) in BV2 cells, although its potency was lower than that of higenamine. Quantitative results (e.g., exact inhibition percentages or IC50) for N-Methylnuciferine were not individually reported in the text or figures. [1]
The compound was one of several active alkaloids from lotus plumule that reduced inflammatory mediators in LPS‑challenged BV2 microglia, as shown in the screening experiments (Fig. 3). [1] |
|---|---|
| Cell Assay |
Murine microglia BV2 cells were cultured in DMEM containing 10% fetal bovine serum. N-Methylnuciferine was dissolved in an appropriate vehicle and added to the culture medium at a concentration of 20 μM for 0.5 h of pretreatment. Thereafter, LPS (0.5 μg/mL) was added, and the cells were incubated for an additional 24 h in DMEM with 3% fetal bovine serum. After treatment, NO production in the culture medium was measured using a Griess reagent kit. For mRNA analysis, total RNA was extracted and converted to cDNA, and the expression levels of iNOS, IL‑1β, IL‑6, and TNF‑α were determined by quantitative real‑time PCR using specific primers and SYBR Green detection. The results showed that N-Methylnuciferine suppressed LPS‑induced NO and pro‑inflammatory cytokine mRNA levels, although the exact numeric values were not specified for this compound alone. [1]
|
| References | |
| Additional Infomation |
N-Methylnuciferine is one of the active alkaloids identified in lotus plumule. In a network pharmacology analysis (using the TCMSP database), seven potential active components of lotus plumule were identified; these included nuciferine and other alkaloids, but N-Methylnuciferine was not explicitly listed among the seven components (the seven components were likely liansinine, neferine, isolinensinine, nuciferine, N‑methylnuciferine, etc.). The compound was obtained from a commercial source (Chengdu Dexter Biotechnology Co., Ltd) and tested in vitro, but it was not selected for in vivo experiments (the in vivo studies focused on total alkaloids and higenamine). [1]
|
| Molecular Formula |
C20H24NO2
|
|---|---|
| Molecular Weight |
310.4101
|
| Exact Mass |
310.181
|
| CAS # |
754919-24-9
|
| PubChem CID |
102004640
|
| Appearance |
White to off-white solid
|
| LogP |
3.559
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
437
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C([H])([H])[H])C1=C(C([H])=C2C([H])([H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])[C@]3([H])C([H])([H])C4=C([H])C([H])=C([H])C([H])=C4C1=C32)OC([H])([H])[H]
|
| InChi Key |
NJSAZXBJMATEKS-MRXNPFEDSA-N
|
| InChi Code |
InChI=1S/C20H24NO2/c1-21(2)10-9-14-12-17(22-3)20(23-4)19-15-8-6-5-7-13(15)11-16(21)18(14)19/h5-8,12,16H,9-11H2,1-4H3/q+1/t16-/m1/s1
|
| Chemical Name |
(6aR)-1,2-dimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~322.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2215 mL | 16.1077 mL | 32.2155 mL | |
| 5 mM | 0.6443 mL | 3.2215 mL | 6.4431 mL | |
| 10 mM | 0.3222 mL | 1.6108 mL | 3.2215 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
